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Sphingosine-1-phosphate promotes the
differentiation of adipose-derived stem cells into
endothelial nitric oxide synthase (eNOS)
expressing endothelial-like cells
Divya Arya1, Shaohua Chang1, Paul DiMuzio2, Jeffrey Carpenter1 and Thomas N Tulenko1*

Abstract
Background: Adipose tissue provides a readily available source of autologous stem cells. Adipose-derived stem cells
(ASCs) have been proposed as a source for endothelial cell substitutes for lining the luminal surface of tissue engineered
bypass grafts. Endothelial nitric oxide synthase (eNOS) is a key protein in endothelial cell function. Currently, endothelial
differentiation from ASCs is limited by poor eNOS expression. The goal of this study was to investigate the role of three
molecules, sphingosine-1-phosphate (S1P), bradykinin, and prostaglandin-E1 (PGE1) in ASC endothelial differentiation.
Endothelial differentiation markers (CD31, vWF and eNOS) were used to evaluate the level of ASCs differentiation
capability.
Results: ASCs demonstrated differentiation capability toward to adipose, osteocyte and endothelial like cell phenotypes.
Bradykinin, S1P and PGE were used to promote differentiation of ASCs to an endothelial phenotype. Real-time PCR
showed that all three molecules induced significantly greater expression of endothelial differentiation markers CD31, vWF
and eNOS than untreated cells. Among the three molecules, S1P showed the highest up-regulation on endothelial
differentiation markers. Immunostaining confirmed presence of more eNOS in cells treated with S1P than the other
groups. Cell growth measurements by MTT assay, cell counting and EdU DNA incorporation suggest that S1P promotes
cell growth during ASCs endothelial differentiation. The S1P1 receptor was expressed in ASC-differentiated endothelial
cells and S1P induced up-regulation of PI3K.
Conclusions: S1P up-regulates endothelial cell markers including eNOS in ASCs differentiated to endothelial like cells. This
up-regulation appears to be mediated by the up-regulation of PI3K via S1P1 receptor. ASCs treated with S1P offer
promising use as endothelial cell substitutes for tissue engineered vascular grafts and vascular networks.

Background
Adult stem cells, such as endothelial progenitor cells [1,2]
and bone-marrow derived mesenchymal cells [3,4] have
been evaluated for lining the luminal surface of tissue engineered bypass grafts for cardiovascular therapy. The widespread use of these cells in vascular grafts is limited by
harvesting difficulties and decreased availability with advancing age and co-morbidities [5,6]. Adipose tissue provides a
source of autologous stem cells in large quantities through
minimally invasive procedures [7-11] and isolation
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efficiency is not affected by the gender, advanced age, obesity, renal failure, or vascular disease [12]. When grown in
medium with endothelial cell growth supplement, human
adipose-derived stem cells (ASCs) express endothelial
specific markers such as platelet-endothelial cell adhesion
molecule (PCAM-1 or CD31) and von Willebrand’s Factor
(vWF). However, the expression of endothelial nitric oxide
synthase (eNOS) is limited [11,13-15]. eNOS is a key
signaling protein that promotes vascular smooth muscle relaxation, reduces platelet aggregation and provides atheroprotection through the production of nitric oxide [16]. The
presence of eNOS is thus a key marker of endothelial cell
function [17]. Though prior studies have demonstrated that
shear force [11,13], specialized alloys with nanostructures
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[18], polycaporlactone scaffolds [19], and transfection with
adenovirus [10] promote the expression of eNOS in endothelial cells differentiated from ASCs, their use in humans
raises practical concerns of biocompatibility, cost, and
safety. A simple and practical method of promoting eNOS
expression using biologic molecules that are naturally occurring yet easily available is lacking.
This study investigated whether the naturally occurring molecules, sphingosine-1-phosphate (S1P), bradykinin, and prostaglandin-E1 (PGE1) can promote the
differentiation of functional eNOS competent endothelial cells from human ASCs. S1P, a key member of the
sphingolipid group, is a circulating bioactive lipid metabolite that can trigger a wide variety of biological
effects, including cell differentiation, survival, and
angiogenesis [20]. Platelet derived S1P has been identified as an activator of eNOS in bovine cultured vascular
endothelial cells through binding to EDG receptors
[21,22]. S1P is a sphingolipid that acts on 5 types of Gprotein-coupled receptors termed S1P1-S1P5, originally
termed EDG receptors [22,23]. Of these, the S1P1, S1P2
and S1P3 receptors are the predominant receptors
expressed in mammalian cells [24]. S1P1 is involved in
activation of eNOS via phosphoinositide 3-kinase
(PI3K)/Akt (protein kinase B)-mediated phosphorylation [22,25]. In addition to activating eNOS as described above, S1P receptors can also activate MAP
kinase, extracellular-regulated kinase (ERK), phospholipase C (PLC), small guanosine triphosphatase (Rac),
protein kinase C (PKC), adenylate cyclase (cAMP) and
Ras homologous proteins (Rho) as well as increase
intracellular free calcium [26]. The cell type-specific expression of S1P receptors results in a highly complex
master regulatory role of S1P. In normal human lung
microvascular endothelial cells, bradykinin activates
bradykinin B2 receptors that results in activation of
eNOS [27-29]. The PGE1 analogue, alprostadil, has been
shown to increase eNOS production in human umbilical
vein endothelial cells [30,31].
Based on the above reports that S1P, bradykinin, and
PGE1 promote the expression of eNOS in native endothelial cells, we hypothesized that S1P, bradykinin, or PGE1
would up-regulate the expression of endothelial cell differentiation markers (CD31, eNOS, and vWF) in endothelial
cells differentiated from ASCs. Human ASCs were cultured
in endothelial growth medium and exposed to S1P, bradykinin, or PGE1. The effect of S1P, bradykinin, and PGE1 on
expression of eNOS, CD31, and vWF was determined by
quantitative, real-time reverse transcription polymerase
chain reaction (RT-PCR) and confocal microscopy images
of immunostaining. In addition, the effect of S1P on cell
growth and PI3K were also investigated to provide a better
understanding of the underlying mechanism of S1P stimulation on ASC differentiation.
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Methods
ASCs isolation and cell culture

ASCs were isolated from human abdominal liposuction aspirate as approved by the Cooper University Hospital Institutional Review Board Committee. Briefly, the adipose
tissue from liposuction aspirate was rinsed with PBS buffer
and incubated with 0.1% collagenase (Northington) for
1 hour at 37°C with vigorous shaking. After 5 minutes centrifugation (1000 × g), the top lipid layer was removed and
the remaining liquid portion was centrifuged again to collect the residual cell pellet. The cell pellet was treated with
1 ml water for 10 seconds to lyse the red blood cells
followed by a 3rd centrifugation with 10 ml medium. The
cell pellet was then plated into T75 cell culture flask with
M-199 containing 10% FBS and placed into a humidified
tissue culture incubator. The next day, the floating cells
were removed by medium change and the adherent ASCs
were grown to confluence as passage zero cells. Passage 1
or passage 2 cells were used in this study to test the effect
of S1P (Echelon), bradykinin (Sigma) and PGE (Sigma) on
ASCs endothelial differentiation.
ASCs multipotency test

ASCs were cultured in different media based on experimental design. M-199 was used as non-differentiating
maintenance medium. Adipogenic and osteogenic differentiation media were purchased from Invitrogen and endothelial differentiation medium (EGM2) was from Lonza.
Two specific staining methods were used to evaluate adipogenic and osteogenic differentiation, Oil red O (Sigma) for
fat and Alizarin red (Sigma) for calcium deposit. Endothelial differentiation was measured by CD31 expression using
flow cytometry. 5 × 105 cells were prepared for 3 cell lines:
un-differentiated ASCs, ASCs differentiated endothelial like
cells or HUVECs. Then the cells were incubated with antiCD31-FITC (BD Biosciences) for 30 minutes and washed
before analyzed by Accuri C6 flow cytometer (BD
Biosciences).
RNA isolation and real-time polymerase chain reaction
(PCR)

Total RNA was isolated from cultured cells using Trizol
reagent (Life Technologies) according to the manufacturer’s RNA isolation protocol. Reverse Transcription
was performed to transcribe and amplify mRNA into
cDNA using the SuperScriptTM II Reverse Transcriptase
kit (Life Technologies). Real-Time PCR (7500 fast, Applied Biosystem) was used to measure the expression of
eNOS, CD31, and vWF at mRNA level. GAPDH was
used to normalize the expression of the target genes.
Immunostaining and confocal microscopy

Cultured cells were fixed with 4% formalin for 10 minutes and blocked with 5% BSA solution for 1 hour.
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Then the cells were incubated with different specific primary antibodies, eNOS (BD Biosciences), S1P1 (Cayman
Chemical, Ann Arbor, MI) or PI3K (Abcam, Cambridge,
MA) overnight in cold room and the corresponding
AlexaFluor 488 or 594 conjugated secondary antibody
(Molecular Probe) for 1 hour. The slides were then
mounted and viewed under an Olympus confocal microscope and images were captured using Fluoview FV100
software.
Cell growth measured by MTT assay, cell counting and
EdU DNA-incorporation assay

ASCs were cultured in the presence or absence of S1P. For
MTT assay, cell culture was incubated with MTT solution
(Sigma-Aldrich) at 0.5 mg/ml for 2 hours at 37°C. The formazan product was dissolved in 200 μl DMSO then measured at 570 nm for absorbance using SpectroMax
microplate reader (Molecular device). Cell counting was
measured by Coulter counter (Beckman) after cells were
dissociated by trypsin. Lastly, EdU (10 μM) was added to
cultured cells for 2 days incubation. Cells were fixed with
4% formalin. EdU incorporated into the nucleus was detected with azide conjugated with Alexa Fluor™ 488 according to the manufacturer’s instruction (Click-iT™ EdU cell
proliferation kit, Invitrogen). All nuclei were counted with
the aid of DAPI staining.
Western blotting

Protein samples from cultured cells were isolated by using
extraction buffer [50 mM Tris (pH 6.8), 20% glycerol, 1%
SDS, and a protease inhibitors cocktail (Sigma, St. Louis,
MO)]. The protein concentration was determined using the
DC protein assay kit (Bio-Rad, Hercules, CA). 40 μg total
protein from each sample was loaded to 4 – 20% precast
gels for two hours running at 120 V and then transferred to
PVDF membranes overnight at 24 at 4°C. Membrane were
blocked with 5% bovine serum albumin blocking buffer for
1 hr. Primary antibody anti-PI3K (Abcam), anti-S1P1 receptor (Cayman Chemical Company) or anti-β-actin
(Sigma) was incubated at 4°C overnight or 2 hours at room
temperature then followed by 1-h incubation with corresponding secondary antibodies from Molecular Probe. Target protein bands were visualized and quantitated by
scanning with Fluo Chemi Q imager (Protein Simple, Santa
Clara, CA).
Data analysis

Histograms were constructed to compare the relative expression of CD31, eNOS, and vWF in the experimental
group (treated with S1P, bradykinin or PGE1) and untreated
control. Within the experimental group, statistical comparisons were performed by analysis of variance (ANOVA) and
multiple comparisons were done with Tukey’s post hoc
tests. Values were expressed as mean ± SE. Differences were
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considered significant at p < .05. Student t-test was performed to compare the cell growth and PI3K expression
between control and S1P treated cells. Asterisks indicate
statistical significance with p < .05.

Results
ASCs differentiation to adipose, osteocyte and endothelial
like cells

ASCs multipotency was determined using three lineage differentiation pathways, including adipogenic, osteogenic and
endothelial differentiation. Figure 1 shows each differentiation result. In panel A, ASCs grown in adipogenic differentiation medium display Oil red O staining of lipid
droplets while there was no staining in control group. The
formation of lipid droplets is a key feature of adipose cells.
In panel B, ASCs grown in osteogenic differentiation
medium show intensive red staining for calcium deposits
while no staining was observed in control cells. Calcium deposition is a key feature of osteocytes. In panel C, there was
no CD31 expression in undifferentiated ASCs while ASCs
grown with EGM2 expressed endothelial marker CD31
similar to positive HUVECs control.
Effect of S1P, bradykinin, and PGE1 on ASCs endothelial
differentiation

Three molecules were selected to promote ASCs endothelial differentiation and real-time PCR was used to
evaluate up-regulation of related genes. Figure 2 shows
the relative expression of CD31, vWF and eNOS mRNA
in bradykinin, S1P or PGE1 treated groups compared to
untreated cells. Significant differences in CD31 expression were noted between the treated and untreated
groups (p < .01, n = 6). Compared with untreated cells,
S1P increased expression of CD31 by 26-fold, bradykinin
increased CD31 by 4.9-fold, and PGE1 increased CD31
by 7.3-fold. Post-hoc analysis showed that cells treated
with S1P showed significantly greater expression of
CD31 than all the other groups (p < .05, n = 6). Cells
treated with bradykinin, S1P and PGE1 showed similar
trend of up-regulation on vWF expression as CD31.
However, the increase in vWF was much less than that
of CD31. Interestingly, eNOS also showed the similar
trend with even a greater change. Compared with untreated cells, S1P increased expression of eNOS by 43fold, bradykinin increased eNOS expression by 3.9-fold,
and PGE1 increased eNOS by 8.9-fold. Post-hoc analysis
also indicated that cells treated with S1P had significantly greater expression of eNOS than the others
(p < .05, n = 6).
eNOS protein localization by immunostaining and
confocal microscopy

Figure 3 showed a direct visual conformation of eNOS distribution in ASCs differentiated to endothelial like cells
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Figure 1 ASC differentiation to adipose, osteocyte and endothelial like cells. Oil Red O staining was used to detect lipid droplet formation
during adipogenic differentiation (panel A). The left side image depicts control ASCs grown in M-199 medium while the right one shows ASCs
grown in adipogenic differentiation medium. Alizarin Red staining was used to measure calcium deposition during osteogenic differentiation
(panel B). The left side image depicts control ASCs grown in base medium M-199 while the right one shows ASCs grown in osteogenic differentiation
medium. Endothelial differentiation was measured by CD31 flow cytometry (panel C). Left side is undifferentiated ASCs grown in M-199 medium, the
middle is differentiated ASCs grown in EGM2 medium and the right is HUVECs endothelial cell control.

using confocal microscopy. Undifferentiated ASCs were
used as negative control and the endothelial cell line
HUVEC was used as a positive control. Images of immunostaining demonstrated that S1P promoted greater expression of eNOS protein (red fluorescent staining) than the
other groups with the exception of the positive control
HUVEC. This result was consistent with PCR data and further supported S1P promoting ASCs differentiation to an
endothelial cell phenotype. Analysis of cellular morphology
showed that treatment with S1P, bradykinin, or PGE1 resulted in a more organized cell structure. Morphologically,
untreated cells are long, spindle-like, and widely dispersed.
The treated cells have a more organized cell structure with
segregated cell-type partitioning; however their morphology
is not similar to that of HUVEC controls.

Effect of S1P on cell growth during ASCs endothelial
differentiation

Both PCR and immunostaining results demonstrate that
S1P promotes ASCs differentiation to an endothelial cell
phenotype. In addition to the effect of S1P on ASC differentiation, we also evaluated the effect of S1P on cell growth
and proliferation. In this study, multiple methods were used
to evaluate cell growth (Figure 4). Panel A showed MTT
assay, panel B was from direct cell count and panel C measured DNA incorporation during cell growth using EdU
staining to distinguish newly synthesized DNA. All measurement clearly demonstrated a significant increase on cell
viability (panel A), cell growth (panel B) and cell proliferation (panel C) in S1P treated cells. Student t-test showed
statistical significance with p < .05, n = 4.
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Figure 2 The effect of bradykinin (Bra), S1P and PGE on the expression of endothelial differentiation markers CD31, vWF and eNOS in
ASCs differentiated to endothelial-like cells. Real-Time PCR was performed to evaluate target gene expression. GAPDH was used to normalize
target gene expression levels. A no treatment group was used as control to calculate relative expression between treatments groups. Left panel is
for CD31, middle panel is for vWF and right panel is for eNOS. A total n = 6 individual ASC cell lines were tested.

The expression of S1P1 receptor in ASC-differentiated
endothelial cells and the up-regulation of PI3K by S1P

After showing the promoting function of S1P on ASC
endothelial differentiation and cell growth, our next step
was to elucidate underlying mechanism of S1P stimulation. Based on prior studies [25,32], we hypothesized
that S1P1 and PI3K were involved in this process.
Western-blots of four individual cell lines provided a

M-199

EGM2 with PGE

strong evidence of the existence of S1P1 in ASCdifferentiated endothelial cells (Figure 5, panel A).
Immunostaining confirmed the expression of S1P1 by
positive staining and white arrows indicates membrane
localization of S1P1 (Figure 5, panel B). Figure 6 shows
that S1P induced the up-regulation of PI3K in ASCdifferentiated endothelial cells. The PI3K band is increased
in S1P-treated cells (Figure 6, panel A). Analyzed

EGM2

EGM2 with bradykinin

EGM2 with S1P

HUVEC

Figure 3 Immunostaining for eNOS in six different experimental groups. Cells were grown in M-199, EGM2, EGM2 + bradykinin treatment,
EGM2 + PGE treatment, EGM2 + S1P. Red fluorescent staining shows the localization of eNOS. ASCs grown in M-199 served as an undifferentiated
negative control and HUVEC served as positive controls. Cells treated with S1P show greater red fluorescence intensity compared to the
other groups.
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Figure 4 The effect of S1P on cell growth during differentiation of ASCs to the endothelial phenotype. Cell growth was evaluated by
MTT assay (panel A), direct cell count (panel B) and EdU DNA-incorporation kit (panel C). Green staining indicates newly synthesized DNA with
EdU incorporation and blue staining is DAPI staining to highlight nuclei. Four individual ASCs cell lines were used. Each cell line was subcultured
into two identical sets, one for S1P treatment and one without S1P for control. Student t-test was performed to compare the difference between
control and S1P treated cells. *indicated statistical significance with p < .05.

Western-blot data indicated a statistically significant
increase of PI3K in S1P treated cells (Figure 6, panel
B). Immunostaining showed an increased PI3K staining
intensity and the cytoplasmic distribution of PI3K (Figure 6,
panel C). Our results suggest that S1P up-regulates PI3K
likely via the S1P1 receptor.

Discussion
This is the first study to investigate the effect of three
naturally occurring and easily available biological molecules, S1P, bradykinin, and PGE1, in promoting the differentiation of ASCs into an endothelial like cell
phenotype. The main finding of this study is that S1P
up-regulates the expression of the endothelial cell differentiation markers, eNOS, CD31 and vWF in endothelial
like cells differentiated from ASCs. We cultured ASCs in
EGM2 medium, which promotes their differentiation toward an endothelial like cells, and then stimulated the
ASCs with S1P, bradykinin, or PGE1. We observed significant differences in mean expression of CD31 and

eNOS between the treated and untreated groups. Treatment with S1P resulted in 26-fold increase in expression
of CD31, an early marker of endothelial cell differentiation, and 43-fold increase in the expression of eNOS, a
marker of more mature differentiation. Confocal microscopy confirmed higher expression of eNOS in cells
treated with S1P compared to untreated cells. Cell
growth measurements demonstrate that S1P promotes
cell proliferation during ASC-to-endothelial differentiation. We also demonstrated the existence of S1P1 receptor in ASC-differentiated endothelial cells and the
up-regulation of PI3K by S1P. Taken together, these
findings suggest that S1P is a promising molecule that
can promote the differentiation of ASC to an eNOS
competent endothelial cell, a process which may be
driven by up-regulation of PI3K via S1P1 receptor.
In the present study, particular attention was paid to
the isolation process of the stem cells. Stem cell multipotency was assessed for each batch of ASCs isolation.
In order to demonstrate that the ASCs isolated in this
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Figure 5 The expression of S1P1 receptor protein in ASC-differentiated to endothelial-like cells. Panel A: Western-blot for S1P1 and
β-actin in four cell lines of ASC-differentiated endothelial cells. Panel B: Immunostaining for S1P1 and β-actin in ASC-differentiated to endothelial
cells. Red fluorescence is for S1P1, green fluorescence is for β-actin, blue fluorescence is DAPI for nuclei. White arrows show the membrane
distribution of S1P1. Western-blot coupled to immunostaining confirmed the expression of S1P1 in ASC-differentiated to endothelial-like cells.

study were indeed multipotent, we showed differentiation into second cell types, namely adipocytes grown in
adipogenesis induction medium and osteocytes grown in
osteogenesis induction medium. We also set up negative
controls of our experiment, i.e. ASCs grown in base
medium. The negative control did not form lipid droplets or calcium deposits. They also did not express endothelial markers. Thus, these observations indicate that
the increased expression of CD31 and eNOS noted in
these experiments by S1P, bradykinin, or PGE1, was the
result of differentiation rather than a selection bias.
The mechanism through which S1P promotes differentiation of ASCs into endothelial cells is not known.
Prior reports have shown the role of S1P in cell differentiation, e.g., during embryonic development, S1P plays a

critical role in stem cell differentiation and apoptosis
[33,34]. S1P has been shown to promote the differentiation of stem cells into other types of adult cells such as
oligodendroglial lineage [35] and smooth muscle cells
[36]. In native endothelial cells, S1P exerts its action by
binding to a family of G-protein coupled receptors,
called S1P1-S1P5, previously termed as endothelial differentiation gene receptors [21]. S1P induces eNOS activation and endothelial barrier enhancement through
PI3K pathway [22,32]. Prior studies also have shown that
PI3K pathway plays an important role for endothelial
cell differentiation in embryonic stem cells [37,38].
Therefore, we hypothesized that the mechanism of S1P
promotion is also through PI3K pathway. We first
showed the expression and localization of S1P1 receptor
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Figure 6 The up-regulation of PI3K in S1P treated ASC-differentiated endothelial cells. Panel A: Western-blot for PI3K and β-actin in ASCs
(M-199), ASC-differentiated endothelial cells (EGM2) and S1P treated ASC-differentiated endothelial cells (EGM2 + S1P). Panel B: Analyzed
Western-blot data from four ASC cell lines, *indicated statistical significance with p < .05. C: Immunostaining for PI3K and β-actin in
ASC-differentiated endothelial cells. Red fluorescence is for PI3K and green fluorescence is for β-actin. Both Western-blot and immunostaining
demonstrate the up-regulation of PI3K by S1P in ASC-differentiated endothelial cells.

in ASC-differentiated endothelial cells. Then we demonstrated the up-regulation of PI3K by S1P treatment. Our
results suggest that the up-regulation of PI3K by S1P is
likely mediated by the S1P1 receptor, and PI3K upregulation is a likely mechanism through which S1P
promotes ASC differentiation to an eNOS competent
endothelial phenotype. Additional pathways may be involved, but future studies will be required to address
this question.
Of the three molecules, S1P appears to have the greatest potential of promoting expression of markers in
endothelial cells differentiated from ASCs. Though
bradykinin and PGE1 both increased the expression of
CD31, eNOS and vWF, marker expression for bradykinin
and PGE1 treated cells was not as high as S1P group.
Prior studies have reported that PGE1 and bradykinin
promote the expression of eNOS in natural endothelial
cells and the pathways through which such activation
occurs has been described [27,31]. The observed less difference in eNOS expression in the bradykinin and PGE1

groups in our study may be due to the relatively small
sample size. Alternatively, it is possible that endothelial
cells differentiated from ASCs do not have the same response to bradykinin and PGE1 as native endothelial
cells. Future studies will be required to determine if
bradykinin and PGE1 have a supplemental role or a synergistic effect with S1P in promoting endothelial cell
differentiation.
Our findings that S1P promotes differentiation of ASCs
to endothelial cells have considerable implications for future clinical uses. S1P is a polar, bioactive sphingolipid
which can be detected and quantified at nM concentrations
[39]. Given easy accessibility, ASCs incubated with S1P
could offer a ready source of EC-like cells for developing
tissue engineered bypass grafts for cardiovascular therapy
and/or neovascularization therapy in ischemic tissues. Further refinement of techniques, including the use of a combination of molecules and/or biophysical methods will be
required to achieve optimal differentiation of ASCs into
functional endothelial cells.
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Conclusion
In summary, this study provides new information regarding
the use of S1P for stimulating the differentiation of human
ASCs to endothelial-like cells. When cultured in endothelial
growth supplement and exposed to stimulating effect of
S1P, human ASCs showed markedly increased eNOS expression. S1P is a naturally occurring and easily available
biological molecule. Endothelial-like cells differentiated
from ASCs and treated with S1P offer promising use as
endothelial cell substitutes for tissue engineered vascular
grafts and neovascularization.
Abbreviations
ASCs: Adipose-derived stem cells; CD31: Platelet-endothelial cell adhesion
molecule; eNOS: Endothelial nitric oxide synthase; EGM2: Endothelial
differentiation medium; HUVECs: Human umbilical vein endothelial cells;
PGE1: Prostaglandin-E1; S1P: Sphingosine-1-phosphate; vWF: Von willebrand’s
Factor; Bra: Bradykinin.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DA carried out the cell culture, ASC differentiation, PCR, data analysis and
manuscript preparation. SC carried out Western-blot and reviewed manuscript. PD and JC participated project design, data analysis and manuscript
preparation. TT supervised experimental design, data analysis and reviewed
manuscript. All authors read and approved the final manuscript.
Acknowledgements
Support for this study was provided in part from NIH grant R01HL073980
(TNT) and the DOD (contract W81XW H08-2-00 to TNT).
Author details
1
Department of Surgery, Cooper University Hospital and Cooper Medical
School of Rowan University, 3 Cooper Plaza, Camden, NJ 08103, USA.
2
Department of Surgery, Thomas Jefferson University College of Medicine,
1025 College Bldg, Philadelphia, PA 19017, USA.
Received: 5 January 2014 Accepted: 15 May 2014
Published: 4 June 2014
References
1. Sreerekha PR, Krishnan LK: Cultivation of endothelial progenitor cells on
fibrin matrix and layering on dacron/polytetrafluoroethylene vascular
grafts. Artif Organs 2006, 30(4):242–249.
2. Vartanian KB, Kirkpatrick SJ, McCarty OJ, Vu TQ, Hanson SR, Hinds MT:
Distinct extracellular matrix microenvironments of progenitor and
carotid endothelial cells. J Biomed Mater Res A 2009, 91(2):528–539.
3. Hjortnaes J, Gottlieb D, Figueiredo JL, Melero-Martin J, Kohler RH, Bischoff J,
Weissleder R, Mayer JE, Aikawa E: Intravital molecular imaging of smalldiameter tissue-engineered vascular grafts in mice: a feasibility study.
Tissue Eng Part C Methods 2010, 16(4):597–607.
4. Wu YF, Zhang J, Gu YQ, Li JX, Wang LC, Wang ZG: Reendothelialization of
tubular scaffolds by sedimentary and rotative forces: a first step toward
tissue-engineered venous graft. Cardiovasc Revasc Med 2008, 9(4):238–247.
5. Magri D, Fancher TT, Fitzgerald TN, Muto A, Dardik A: Endothelial
progenitor cells: a primer for vascular surgeons. Vascular 2007,
15(6):384–394.
6. Siddiq S, Pamphilon D, Brunskill S, Doree C, Hyde C, Stanworth S: Bone
marrow harvest versus peripheral stem cell collection for haemopoietic
stem cell donation in healthy donors. Cochrane Database Syst Rev 2009,
1, CD006406.
7. Cao Y, Sun Z, Liao L, Meng Y, Han Q, Zhao RC: Human adipose tissue-derived
stem cells differentiate into endothelial cells in vitro and improve postnatal
neovascularization in vivo. Biochem Biophys Res Commun 2005, 332(2):370–379.

Page 9 of 10

8.

9.

10.

11.

12.

13.

14.

15.

16.

17.
18.

19.

20.

21.
22.

23.
24.

25.

26.

27.

28.

29.

DiMuzio P, Fischer L, McIlhenny S, DiMatteo C, Golesorhki N, Grabo D, Tarola
N, Mericli A, Shapiro I, Tulenko T: Development of a tissue-engineered
bypass graft seeded with stem cells. Vascular 2006, 14(6):338–342.
Harris LJ, Zhang P, Abdollahi H, Tarola NA, DiMatteo C, McIlhenny SE,
Tulenko TN, DiMuzio PJ: Availability of adipose-derived stem cells in
patients undergoing vascular surgical procedures. J Surg Res 2010,
163(2):e105–e112.
McIlhenny S, Zhang P, Tulenko T, Comeau J, Fernandez S, Policha A, Ferroni
M, Faul E, Bagameri G, Shapiro I, Dimuzio P: eNOS transfection of adiposederived stem cells yields bioactive nitric oxide production and improved
results in vascular tissue engineering. J Tissue Eng Regen Med 2013, Epub
ahead of print.
Zhang P, Moudgill N, Hager E, Tarola N, Dimatteo C, McIlhenny S, Tulenko T,
DiMuzio PJ: Endothelial differentiation of adipose-derived stem cells from
elderly patients with cardiovascular disease. Stem Cells Dev 2011,
20(6):977–988.
DiMuzio P, Tulenko T: Tissue engineering applications to vascular bypass
graft development: the use of adipose-derived stem cells. J Vasc Surg
2007, 45(Suppl A):A99–A103.
Fischer LJ, McIlhenny S, Tulenko T, Golesorkhi N, Zhang P, Larson R,
Lombardi J, Shapiro I, DiMuzio PJ: Endothelial differentiation of adiposederived stem cells: effects of endothelial cell growth supplement and
shear force. J Surg Res 2009, 152(1):157–166.
Hristov M, Weber C: Endothelial progenitor cells: characterization,
pathophysiology, and possible clinical relevance. J Cell Mol Med 2004,
8(4):498–508.
Ning H, Liu G, Lin G, Yang R, Lue TF, Lin CS: Fibroblast growth factor 2
promotes endothelial differentiation of adipose tissue-derived stem cells.
J Sex Med 2009, 6(4):967–979.
Ahanchi SS, Tsihlis ND, Kibbe MR: The role of nitric oxide in the
pathophysiology of intimal hyperplasia. J Vasc Surg 2007,
45(Suppl A):A64–A73.
Sessa WC: eNOS at a glance. J Cell Sci 2004, 117(Pt 12):2427–2429.
Shi Z, Neoh KG, Kang ET: In vitro endothelialization of cobalt chromium
alloys with micro/nanostructures using adipose-derived stem cells.
J Mater Sci Mater Med 2013, 24(4):1067–1077.
Marino G, Rosso F, Ferdinando P, Grimaldi A, De Biasio G, Cafiero G, Barbarisi
M, Barbarisi A: Growth and endothelial differentiation of adipose stem
cells on polycaprolactone. J Biomed Mater Res A 2012, 100(3):543–548.
Liu X, Zhang QH, Yi GH: Regulation of metabolism and transport of
sphingosine-1-phosphate in mammalian cells. Mol Cell Biochem 2012,
363(1–2):21–33.
Igarashi J, Michel T: S1P and eNOS regulation. Biochim Biophys Acta 2008,
1781(9):489–495.
Igarashi J, Bernier SG, Michel T: Sphingosine 1-phosphate and activation
of endothelial nitric-oxide synthase. differential regulation of Akt and
MAP kinase pathways by EDG and bradykinin receptors in vascular
endothelial cells. J Biol Chem 2001, 276(15):12420–12426.
Ishii I, Fukushima N, Ye X, Chun J: Lysophospholipid receptors: signaling
and biology. Annu Rev Biochem 2004, 73:321–354.
Zhang G, Contos JJ, Weiner JA, Fukushima N, Chun J: Comparative analysis
of three murine G-protein coupled receptors activated by sphingosine-1phosphate. Gene 1999, 227(1):89–99.
Di Villa Bianca R, Sorrentino R, Sorrentino R, Imbimbo C, Palmieri A, Fusco F,
Maggi M, De Palma R, Cirino G, Mirone V: Sphingosine 1-phosphate
induces endothelial nitric-oxide synthase activation through
phosphorylation in human corpus cavernosum. J Pharmacol Exp Ther 2006,
316(2):703–708.
Brinkmann V: Sphingosine 1-phosphate receptors in health and disease:
mechanistic insights from gene deletion studies and reverse
pharmacology. Pharmacol Ther 2007, 115(1):84–105.
Kuhr F, Lowry J, Zhang Y, Brovkovych V, Skidgel RA: Differential regulation
of inducible and endothelial nitric oxide synthase by kinin B1 and B2
receptors. Neuropeptides 2010, 2010(44):145–154.
Sangsree S, Brovkovych V, Minshall RD, Skidgel RA: Kininase I-type
carboxypeptidases enhance nitric oxide production in endothelial cells
by generating bradykinin B1 receptor agonists. Am J Physiol Heart Circ
Physiol 2003, 284(6):H1959–H1968.
Venema RC: Post-translational mechanisms of endothelial nitric oxide
synthase regulation by bradykinin. Int Immunopharmacol 2002,
2(13–14):1755–1762.

Arya et al. Journal of Biomedical Science 2014, 21:55
http://www.jbiomedsci.com/content/21/1/55

Page 10 of 10

30. Fang WT, Li HJ, Zhou LS: Protective effects of prostaglandin E1 on human
umbilical vein endothelial cell injury induced by hydrogen peroxide.
Acta Pharmacol Sin 2010, 31(4):485–492.
31. Haider DG, Bucek RA, Giurgea AG, Maurer G, Glogar H, Minar E, Wolzt M,
Mehrabi MR, Baghestanian M: PGE1 analog alprostadil induces VEGF and
eNOS expression in endothelial cells. Am J Physiol Heart Circ Physiol 2005,
289(5):H2066–H2072.
32. Singleton PA, Dudek SM, Chiang ET, Garcia JG: Regulation of sphingosine
1-phosphate-induced endothelial cytoskeletal rearrangement and barrier
enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alphaactinin. FASEB J 2005, 19(12):1646–1656.
33. Hojjati MR, Li Z, Jiang XC: Serine palmitoyl-CoA transferase (SPT)
deficiency and sphingolipid levels in mice. Biochim Biophys Acta 2005,
1737(1):44–51.
34. Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL: Essential
role for sphingosine kinases in neural and vascular development.
Mol Cell Biol 2005, 25(24):11113–11121.
35. Bieberich E: There is more to a lipid than just being a fat: sphingolipidguided differentiation of oligodendroglial lineage from embryonic stem
cells. Neurochem Res 2011, 36(9):1601–1611.
36. Nincheri P, Luciani P, Squecco R, Donati C, Bernacchioni C, Borgognoni L,
Luciani G, Benvenuti S, Francini F, Bruni P: Sphingosine 1-phosphate
induces differentiation of adipose tissue-derived mesenchymal stem
cells towards smooth muscle cells. Cell Mol Life Sci 2009, 66(10):1741–1754.
37. Bekhite MM, Finkensieper A, Binas S, Müller J, Wetzker R, Figulla HR, Sauer H,
Wartenberg M: VEGF-mediated PI3K class IA and PKC signaling in
cardiomyogenesis and vasculogenesis of mouse embryonic stem cells.
J Cell Sci 2011, 124(Pt 11):1819–1830.
38. Sauer H, Rahimi G, Hescheler J, Wartenberg M: Role of reactive oxygen
species and phosphatidylinositol 3-kinase in cardiomyocyte
differentiation of embryonic stem cells. FEBS Lett 2000, 476:218–223.
39. He X, Huang C, Schuchman E: Quantitative analysis of sphingosine-1phosphate by HPLC after nathalene-2,3-dicarboxaldehyde (NDA)
derivatization. J Chromatogr B 2009, 877(10):983–990.
doi:10.1186/1423-0127-21-55
Cite this article as: Arya et al.: Sphingosine-1-phosphate promotes the
differentiation of adipose-derived stem cells into endothelial nitric
oxide synthase (eNOS) expressing endothelial-like cells. Journal of
Biomedical Science 2014 21:55.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at
www.biomedcentral.com/submit

